Revance Therapeutics, Inc. (NASDAQ: RVNC) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $11.00 price target on the stock, down previously from $20.00.
Revance Therapeutics, Inc. (NASDAQ: RVNC) had its price target lowered by analysts at Needham & Company LLC from $18.00 to $12.00. They now have a "buy" rating on the stock.
Revance Therapeutics, Inc. (NASDAQ: RVNC) had its price target lowered by analysts at Mizuho from $9.00 to $8.00. They now have a "neutral" rating on the stock.
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Lags Revenue Estimates [Yahoo! Finance]
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update [Yahoo! Finance]